Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.107 (
DAT
)
1,471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A total of 1044 children selected in age groups of 4, 8 and 12 years old from 12 countries (cities) with stratified random sampling method were monitored on the present situation of immune levels according to the programme on immunization in 1991. The results showed that the positive rates and the geometric mean titers of antibodies to measles were 87.16% +/- 3.14%, 5.83 +/- 0.41 (56.90%, < 1:8), respectively; to
pertussis
were 78.13% +/- 9.19% 218.10 +/- 23.39 (41.62%, > or = 1:320); to
DAT
were 74.4% +/- 11.04%, 0.098 +/- 0.025; to TAT were 75.86% +/- 11.09%, 0.136 +/- 0.03; to poliomyelitis (ELISA) were type I 89.99%, 220.51, type II 83.38%, 201.27, type III 86.09%, 275.08, 3 types 79.48%, 255.91 (27.23%, > or = 1:400); to Japanese B encephalitis (HI) were 67.47% +/- 3.34%, 39.44 +/- 1.48. The conversion of OT was 24.73%. It showed significant difference among these counties and among 3 age groups (P < 0.01). In 4-year age group, the vaccinated rate and the result of immune surveillance were the same. The antibody level and the incidence of measles showed negative correlation.
...
PMID:[The surveillance on the present situation of immune levels of 1044 children vaccinated with seven kinds of vaccines in Dali Prefecture]. 783 90
Mounting evidence supports the idea that neurotransmitter transporters are subject to many forms of post-translational regulation typically associated with receptors and ion channels, including receptor and kinase-mediated changes in transporter phosphorylation, cell surface trafficking, and/or catalytic activation. Although hints of this regulation can be achieved with traditional radiolabeled substrate flux techniques, higher resolution methods are needed that can localize transporter function in situ as well as permit real-time monitoring of transport function without confounds associated with coincident receptor activation. The elegant study by Bolan et al. (p. 1222) capitalizes on the fluorescent properties of a recently introduced substrate for the dopamine (DA) transporter (
DAT
), termed 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP+), to illuminate a
pertussis
toxin-sensitive, extracellular signal-regulated kinase (ERK1/2)-dependent pathway by which presynaptic DA D(2) receptors regulate DATs.
...
PMID:All aglow about presynaptic receptor regulation of neurotransmitter transporters. 1726 64